New blog item 4

Lorem ipsum blog title Lorem ipsum dolor sit amet, consectetur adipiscing elit. Phasellus at nibh iaculis, consequat orci in, fringilla lorem. Integer malesuada justo dapibus vulputate ultrices. Cras at nibh dapibus lorem accumsan viverra vel sit amet tortor. Nunc pellentesque tortor sem. Ut odio purus, ornare aliquam tellus a, pulvinar scelerisque risus. Nulla semper at…

New blog item 3

Lorem ipsum blog title Lorem ipsum dolor sit amet, consectetur adipiscing elit. Phasellus at nibh iaculis, consequat orci in, fringilla lorem. Integer malesuada justo dapibus vulputate ultrices. Cras at nibh dapibus lorem accumsan viverra vel sit amet tortor. Nunc pellentesque tortor sem. Ut odio purus, ornare aliquam tellus a, pulvinar scelerisque risus. Nulla semper at…

New blog item 2

Lorem ipsum blog title Lorem ipsum dolor sit amet, consectetur adipiscing elit. Phasellus at nibh iaculis, consequat orci in, fringilla lorem. Integer malesuada justo dapibus vulputate ultrices. Cras at nibh dapibus lorem accumsan viverra vel sit amet tortor. Nunc pellentesque tortor sem. Ut odio purus, ornare aliquam tellus a, pulvinar scelerisque risus. Nulla semper at…

New blog item

Lorem ipsum blog title Lorem ipsum dolor sit amet, consectetur adipiscing elit. Phasellus at nibh iaculis, consequat orci in, fringilla lorem. Integer malesuada justo dapibus vulputate ultrices. Cras at nibh dapibus lorem accumsan viverra vel sit amet tortor. Nunc pellentesque tortor sem. Ut odio purus, ornare aliquam tellus a, pulvinar scelerisque risus. Nulla semper at…

Intravacc announces positive pre-clinical data for its OMV-based Lyme vaccine

Intravacc announces positive pre-clinical data for its OMV-based Lyme vaccine Bilthoven, the Netherlands, 13 April 2021 – Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced positive preclinical data for its OMV based Lyme disease vaccine. Publication of this study in the peer reviewed scientific journal Vaccine titled “Vaccination…

Intravacc announces positive pre-clinical data for its SARS-CoV-2 nose spray vaccine

Intravacc announces positive pre-clinical data for its SARS-CoV-2 nose spray vaccine Bilthoven, the Netherlands, 7 April 2021 – Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced that it has obtained positive pre-clinical results for its SARS-CoV-2 Outer Membrane Vesicle (OMV) based recombinant Spike protein (rSp) candidate nose spray…

Intravacc Announces Appointment of Nathalie Laarakker as Chief Financial Officer

Intravacc Announces Appointment of Nathalie Laarakker as Chief Financial Officer Bilthoven, the Netherlands, 24 March 2021 – Intravacc, a world leader in translational research and development of vaccines, today announced the appointment of Nathalie Laarakker as Chief Financial Officer and member of the company’s executive management team, with effect from April 1, 2021. Mrs. Nathalie Laarakker…

Intravacc announces formation of Scientific Advisory Board

Intravacc announces formation of Scientific Advisory Board Bilthoven, the Netherlands, 23 February 2021 – Intravacc, a world leader in translational research and development of vaccines, today announced the formation of a Scientific Advisory Board (“SAB”), chaired by Intravacc’s Chief Scientific Officer Virgil Schijns and further comprising scientific leaders in the fields of vaccinology, infectious diseases…